CompanyCING CINGWNasdaqKansas City, KS

Cingulate Inc.

Cingulate develops pharmaceutical products using its PTR drug delivery platform.

SEC EDGAR ClinicalTrials.gov cingulate.com

10-KSep 18Latest SEC filing, period to Jun 30

Aug 13Latest story

August 2026

Cingulate reports Q2 2026 results, updates CTx-1301 CMC and NDA resubmission plans

Aug 13Quarterly updateCingulate Inc.

July 2026

Cingulate eliminates chief legal officer role, Patel to depart in August

Jul 23PeopleCingulate Inc.

Cingulate holds annual meeting, restructures board, expands equity plan

Jul 14PeopleCingulate Inc.

Cingulate posts Phase 3 CTx-1301 classroom results in ADHD, more than two years after trial ended

Jul 2Trial updateCingulate Inc.

Cingulate added to Russell 3000E Index, extends CMO's employment trial period

Jul 2PeopleCingulate Inc.